Provided By Business Wire
Last update: Apr 18, 2025
Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.
The release was issued in error by Aditxt, Inc.
A replacement release will not be issued at this time.
NASDAQ:ADTX (8/18/2025, 9:56:10 AM)
1.03
+0.01 (+0.98%)
Find more stocks in the Stock Screener